Patents by Inventor Kristin Strumane
Kristin Strumane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293680Abstract: The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide dmg. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.Type: ApplicationFiled: July 23, 2021Publication date: September 21, 2023Inventors: Hilma VAN DER HORST, Tuna MUTIS, Kristin STRUMANE, Esther BREIJ, Marije OVERDIJK
-
Publication number: 20230107363Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.Type: ApplicationFiled: May 16, 2022Publication date: April 6, 2023Inventors: Rob DE JONG, Frank Beurskens, Marije Overdijk, Kristin STRUMANE, Janine Schuurman, Paul Parren
-
Publication number: 20220411522Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: March 1, 2022Publication date: December 29, 2022Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20220332801Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.Type: ApplicationFiled: November 24, 2021Publication date: October 20, 2022Inventors: Annemarie KUIPERS, Kok VAN KESSEL, Frank BEURSKENS, Rob DE JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos VAN STRIJP, Suzan ROOIJAKKERS
-
Publication number: 20210324096Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: December 1, 2020Publication date: October 21, 2021Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20210324105Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.Type: ApplicationFiled: January 14, 2021Publication date: October 21, 2021Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
-
Publication number: 20210238296Abstract: Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.Type: ApplicationFiled: May 3, 2019Publication date: August 5, 2021Inventors: Rob DE JONG, Frank BEURSKENS, Simone OOSTINDIE, Aran Frank LABRIJN, Kristin STRUMANE, Janine SCHUURMAN, Bart-Jan DE KREUK
-
Publication number: 20210107988Abstract: The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.Type: ApplicationFiled: January 24, 2019Publication date: April 15, 2021Inventors: Simone OOSTINDIE, Andreas HOLLENSTEIN, Frank BEURSKENS, Kristin STRUMANE, Janine SCHUURMAN, Rob DE JONG
-
Patent number: 10882913Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: GrantFiled: June 25, 2019Date of Patent: January 5, 2021Assignee: GENMAB B.V.Inventors: Marije Overdijk, Kristin Strumane, Rik Rademaker, Esther Breij, Janine Schuurman, Paul Parren
-
Publication number: 20200181277Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.Type: ApplicationFiled: February 12, 2018Publication date: June 11, 2020Inventors: Frank BEURSKENS, Marije OVERDIJK, Annieck M. DIKS, Rob DE JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20200123237Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.Type: ApplicationFiled: May 17, 2017Publication date: April 23, 2020Applicant: Genmab B.V.Inventors: Annemarie KUIPERS, Kok van KESSEL, Frank BEURSKENS, Rob de JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos van STRIJP, Suzan ROOIJAKKERS
-
Publication number: 20190315877Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: June 25, 2019Publication date: October 17, 2019Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20190276549Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.Type: ApplicationFiled: November 1, 2017Publication date: September 12, 2019Applicant: GENMAB B.V.Inventors: Rob DE JONG, Frank BEURSKENS, Marije OVERDIJK, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20190202926Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: December 1, 2016Publication date: July 4, 2019Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20190144554Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: ApplicationFiled: December 1, 2016Publication date: May 16, 2019Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20170369590Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.Type: ApplicationFiled: May 18, 2017Publication date: December 28, 2017Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
-
Publication number: 20140170148Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.Type: ApplicationFiled: April 20, 2012Publication date: June 19, 2014Applicant: GENMAB A/SInventors: Bart De Goeij, Patrick Van Berkel, Kristin Strumane, Aran Frank Labrijn, Joost J. Neijssen, Joyce I. Meesters, Paul Parren, Janine Schuurman
-
Patent number: 7569668Abstract: Described is a method of modulating E-cadherin mediated cell adhesion. More specifically, described is the use of hECRep1a and homologues thereof to modulate and/or control tumor cell invasiveness.Type: GrantFiled: June 16, 2006Date of Patent: August 4, 2009Assignees: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Frans Van Roy, Geert Berx, Kristin Strumane
-
Publication number: 20070066803Abstract: Described is a method of modulating E-cadherin mediated cell adhesion. More specifically, described is the use of hECRep1a and homologues thereof to modulate and/or control tumor cell invasiveness.Type: ApplicationFiled: June 16, 2006Publication date: March 22, 2007Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Frans Roy, Geert Berx, Kristin Strumane
-
Publication number: 20050089896Abstract: Described is a method of modulating E-cadherin mediated cell adhesion. More specifically, described is the use of hECRep1a and homologues thereof to modulate and/or control tumor cell invasiveness.Type: ApplicationFiled: August 20, 2004Publication date: April 28, 2005Inventors: Frans Roy, Geert Berx, Kristin Strumane